DUBLIN - Horizon Therapeutics plc (Nasdaq: HZNP) today announced changes to its research and development organization structure.

Effective immediately, Elizabeth H.Z. Thompson, Ph.D., group vice president, clinical development and external search; Srini Ramanathan, Ph.D., group vice president, development sciences and San Francisco site head and Melanie Gloria, senior vice president, R&D operations, will report to Timothy Walbert, chairman, president and chief executive officer.

In addition, Scott Brun, M.D. will serve as senior advisor to the R&D leadership team. Scott is an accomplished physician executive with more than 20 years of wide-ranging drug development and business development experience. Most recently, Scott served as vice president of scientific affairs and head of AbbVie Ventures, a corporate venture fund responsible for investment opportunities within the company's R&D therapeutic focus areas.

Shao-Lee Lin, M.D., Ph.D., executive vice president, research and development and chief scientific officer is no longer with the Company and a search will be initiated in the near-term for her replacement.

'During the last two years, we have made significant progress in building an R&D team and pipeline, including the development and early approval of TEPEZZA as well as expanding the clinical profile of KRYSTEXXA,' said Timothy Walbert, chairman, president and chief executive officer, Horizon. 'Liz, Srini and Melanie have been integral to our R&D success and I am confident that their collective leadership, along with Scott's experience, will set us up for long-term success. I would like to thank Shao-Lee for her contributions to Horizon's growth and wish her the best of luck in her future endeavors.'

About Horizon

Horizon is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives.

Forward Looking Statements

This press release contains forward-looking statements, including, but not limited to, statements related to anticipated changes in Horizon's R&D team and reporting structure; future results of Horizon's R&D initiatives and business and other statements that are not historical facts. These forward-looking statements are based on Horizon's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks relating to Horizon's ability to successfully implement its business strategies; risks inherent in developing novel medicine candidates and existing medicines for new indications; risks associated with regulatory approvals; risks in the ability to recruit, train and retain qualified personnel and those risks detailed from time-to-time under the caption 'Risk Factors' and elsewhere in Horizon's filings and reports with the SEC. Horizon undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.

Contact:

Geoff Curtis

Email: media@horizontherapeutics.com

(C) 2020 Electronic News Publishing, source ENP Newswire